Alnylam Pharmaceuticals, Inc. (
Q3 2010 Results Conference Call
November 3, 2010 4:30 PM ET
Cynthia Clayton – Senior Director of IR and Corporate Communications
John Maraganore – CEO
Akshay Vaishnaw – SVP, Clinical Research
Patty Allen – VP of Finance and Treasurer
Barry Greene – President and COO
Marko Kozul – ThinkEquity
Ted Tenthoff – Piper Jaffray
Keay Nakae – Chardan Capital
Alan Carr – Needham & Company
Steven Willey – Stifel Nicolaus
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss the third quarter 2010 activities and financial results.
There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company’s request.
I’d now like to hand the call over to Alnylam.
Good afternoon. I’m Cynthia Clayton, Senior Director of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Barry Greene, our President and Chief Operating Officer; Akshay Vaishnaw, Senior Vice President, Clinical Research; and Patty Allen, Vice President of Finance and Treasurer. In addition, Laurence Reid, our Chief Business Officer is also on the call and available for Q&A.
For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investors page of our website, www.alnylam.com.
During today’s call, as outlined on Slide 2, John will provide some introductory remarks and general context, Akshay will summarize our clinical and preclinical R&D activities, Patty will review our financials and guidance, and Barry will summarize our business highlights and goals. We will then open the call for your questions.